scPharmaceuticals Inc. (SCPH)
| Market Cap | 128.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -28.03M |
| Shares Out | 27.37M |
| EPS (ttm) | -1.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,978 |
| Open | 4.61 |
| Previous Close | 4.44 |
| Day's Range | 4.61 - 4.72 |
| 52-Week Range | 3.48 - 7.28 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 10.54 (+124.7%) |
| Earnings Date | May 11, 2022 |
About SCPH
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for SCPH stock is "Buy." The 12-month stock price forecast is 10.54, which is an increase of 124.73% from the latest price.
News
scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
FDA assigns PDUFA action date of October 8, 2022
scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX® New Drug Application
PDUFA action date set for October 8, 2022
scPharmaceuticals Inc. Announces Resubmission of FUROSCIX® New Drug Application
Anticipates Q4 2022 commercial launch, if approved Anticipates Q4 2022 commercial launch, if approved
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Successfully completed all testing; plan to re-submit FUROSCIX® NDA by April 15, 2022
scPharmaceuticals to Present at the 42nd Annual Cowen Healthcare Conference
BURLINGTON, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...
scPharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
BURLINGTON, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...
scPharmaceuticals Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
All additional testing of devices manufactured on the planned commercial line, as required by the FDA, has been successful to date
scPharmaceuticals to Present at the Jefferies London Healthcare Conference
BURLINGTON, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...
scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Sc...
Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX® versus a historical comparator group
scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimi...
scPharmaceuticals Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX® NDA; no additional clinical data or device modifications required at this time; on track f...
scPharma's Furoscix Can Potentially Cut Hospital Admission/Readmission Costs For Heart Failure Patients
scPharmaceuticals Inc (NASDAQ: SCPH) announced top-line results from its FREEDOM-HF study evaluating overall and heart failure-related costs of treating congestion in patients with chronic heart failure...
scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study
Reduced average 30-day heart failure related costs by $17,753 (p
scPharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
BURLINGTON, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize...
scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
FREEDOM clinical study on track for topline results in Q3 2021
ScPharmaceuticals Sees US Application Submission For Furoscix In Q3
ScPharmaceuticals Inc (NASDAQ: SCPH) announced that after the Type A meeting with the FDA, the agency does not require any modifications to the device, nor it asked the company to conduct additional cli...
scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D.
BURLINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...
scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference
BURLINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of scPharmaceuticals Inc. - SCPH
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of scPharmaceuticals Inc. ("scPharmaceuticals" or the "Company") (NASDAQ: SCPH). uch investors are ad...
scPharmaceuticals (SCPH) Plunges on Complete Response Letter
scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in adult pati...
FDA Rejects scPharma's Heart Failure Drug For Second Time, Sending Biotech Stock Lower
Scpharmaceuticals Inc (NASDAQ: SCPH) shares were hurtling toward their late March lows Monday after a binary event panned out negatively for the biopharma. What Happened: Burlington, Massachusetts-based...
scPharmaceuticals to Present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference
BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...
scPharmaceuticals Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update
Commercial ization preparedness activities continuing ahead of December 30 PDUFA date for FUROS C IX ® (furosemide injection) for subcutaneous administration
scPharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...